Scarica l'app Stockscreener
26.11
6.61%
1.62
Dopo l'orario di chiusura:
25.66
-0.45
-1.72%
Precedente Chiudi:
$24.49
Aprire:
$24.38
Volume 24 ore:
166.64K
Relative Volume:
8.44
Capitalizzazione di mercato:
$673.08M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+4.44%
1M Prestazione:
+0.00%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$23.00
$26.52
Intervallo di 1 settimana:
$21.24
$26.52
Portata 52W:
$17.50
$28.98
Faeth Therapeutics Inc Stock (FTH) Company Profile
Nome
Faeth Therapeutics Inc
Settore
Industria
Telefono
(240) 243-8000
Indirizzo
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare FTH vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FTH
Faeth Therapeutics Inc
|
26.11 | 631.32M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Faeth Therapeutics Inc Borsa (FTH) Ultime notizie
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
BTIG Maintains Faeth Therapeutics(FTH.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Faeth Therapeutics CFO Stephenson buys $326,127 in FTH stock By Investing.com - Investing.com Australia
Faeth Therapeutics (FTH) CFO adds 13,634 shares via trust purchases - Stock Titan
Form 4 Faeth Therapeutics, Inc For: 1 July By Investing.com - Investing.com India
Faeth Therapeutics CFO Stephenson buys $326,127 in FTH stock - Investing.com
FTH SEC FilingsFaeth Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition - Stocktwits
FTHFaeth Therapeutics Inc Latest SEC Filings - Finviz
Faeth Therapeutics, Inc.(NasdaqCM:FTH) added to Russell Microcap Value Benchmark Index - marketscreener.com
Faeth Therapeutics, Inc.(NasdaqCM:FTH) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Faeth Therapeutics, Inc.(NasdaqCM: FTH) added to Russell 3000E Growth Benchmark - marketscreener.com
Faeth Therapeutics, Inc.(NasdaqCM: FTH) added to Russell Microcap Index - marketscreener.com
Faeth Therapeutics, Inc.(NasdaqCM: FTH) added to Russell 3000E Value Benchmark - marketscreener.com
Total current assets of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Faeth Therapeutics CFO Stephenson acquires $401,268 in stock By Investing.com - Investing.com Nigeria
Form 4 Faeth Therapeutics, Inc For: 26 June By Investing.com - Investing.com Australia
Faeth Therapeutics CFO Stephenson acquires $401,268 in stock - Investing.com
Faeth Therapeutics (FTH) CFO adds 15,641 shares via trust purchases - Stock Titan
FTH Initiates Coverage On Faeth Therapeutics -- Price Target Set at $57 - GuruFocus
This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Baird Initiates Faeth Therapeutics(FTH.US) With Buy Rating, Announces Target Price $57 - Moomoo
Baird Initiates Faeth Therapeutics at Outperform With $57 Price Target - marketscreener.com
Enterprise value to revenue forward of Faeth Therapeutics, Inc. – MUN:4070 - TradingView
Enterprise value to EBIT forward of Faeth Therapeutics, Inc. – MUN:4070 - TradingView
Baird initiates Faeth Therapeutics stock with outperform rating By Investing.com - Investing.com Nigeria
Price to sales forward of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Baird initiates Faeth Therapeutics stock with outperform rating - Investing.com
Enterprise value to EBITDA forward of Faeth Therapeutics, Inc. – MUN:4070 - TradingView
This Principal Financial Group Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday - Sahm
Price to earnings forward of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Faeth Therapeutics CEO Anand Parikh buys $55,446 in common stock By Investing.com - Investing.com India
FTH | Faeth Therapeutics, Inc. Common Institutional Ownership - Quiver Quantitative
Price to book forward of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
FTH Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Anand Parikh Increases Stake in Faeth Therapeutics Inc - GuruFocus
Faeth Therapeutics CEO Anand Parikh buys $55,446 in common stock - Investing.com UK
Faeth therapeutics CFO Brian C. Stephenson buys $405,920 in stock - Investing.com UK
Faeth therapeutics CFO Brian C. Stephenson buys $405,920 in stock By Investing.com - Investing.com Nigeria
FAETH THERAPEUTICS INC (FTH) Stock Chart - ChartMill
Form 4 Faeth Therapeutics, Inc For: 24 June By Investing.com - Investing.com Australia
FTH | Faeth Therapeutics, Inc. Common Stock Data, Price & News - Quiver Quantitative
Faeth Therapeutics (FTH) CFO adds 17,413 shares via revocable trust purchases - Stock Titan
Faeth Therapeutics CEO buys shares, exercises options | FTH Insider Trading - Stock Titan
Faeth Therapeutics Inc Azioni (FTH) Dati Finanziari
Non sono disponibili dati finanziari per Faeth Therapeutics Inc (FTH). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Faeth Therapeutics Inc Azioni (FTH) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| STEPHENSON BRIAN C | Chief Financial Officer |
Jul 01 '26 |
Buy |
23.50 |
5,000 |
117,492 |
46,688 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 29 '26 |
Buy |
23.34 |
831 |
19,396 |
33,885 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 24 '26 |
Buy |
26.13 |
9,391 |
245,360 |
26,804 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 26 '26 |
Buy |
24.95 |
6,250 |
155,908 |
33,054 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 23 '26 |
Buy |
24.36 |
9,230 |
224,806 |
17,413 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 22 '26 |
Buy |
22.13 |
8,183 |
181,115 |
8,183 |
| Parikh Anand Kiran | President and CEO |
Jun 22 '26 |
Option Exercise |
1.16 |
53,465 |
62,019 |
817,699 |
| Parikh Anand Kiran | President and CEO |
Jun 22 '26 |
Buy |
19.76 |
2,806 |
55,447 |
764,234 |
| Cambrian BioPharma Inc | 10% Owner |
Jun 01 '26 |
Sale |
20.02 |
25,000 |
500,543 |
130,142 |
| Peyer James | 10% Owner |
Jun 01 '26 |
Sale |
20.02 |
25,000 |
500,543 |
130,142 |
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):